4 September 2017
Mainstay Medical Announces Date for 2017 Half Year Results
Dublin – Ireland, 4 September 2017 – Mainstay Medical International plc (“Mainstay” or the “Company”, Euronext Paris: MSTY.PA and ESM of the Irish Stock Exchange: MSTY.IE), a medical device company focused on bringing to market ReActiv8®, an implantable restorative neurostimulation system to treat disabling Chronic Low Back Pain (“CLBP”), will release its 2017 Half Year Results on Tuesday 5 September 2017 at 07:00am BST (02:00 EDT).
The results press release will be available on the “Investors” section of the Mainstay Medical website at http://www.mainstay-medical.com/en/investors
- End -
Mainstay is a medical device company focused on bringing to market an innovative implantable restorative neurostimulation system, ReActiv8®, for people with disabling Chronic Low Back Pain (CLBP). The Company is headquartered in Dublin, Ireland. It has subsidiaries operating in Ireland, the United States, Australia and Germany, and its ordinary shares are admitted to trading on Euronext Paris (MSTY.PA) and the ESM of the Irish Stock Exchange (MSTY.IE).
About Chronic Low Back Pain
One of the recognized root causes of CLBP is impaired control by the nervous system of the muscles that dynamically stabilize the spine in the low back, and an unstable spine can lead to back pain. ReActiv8 is designed to electrically stimulate the nerves responsible for contracting these muscles and thereby help to restore muscle control and improve dynamic spine stability, allowing the body to recover from CLBP.
People with CLBP usually have a greatly reduced quality of life and score significantly higher on scales for pain, disability, depression, anxiety and sleep disorders. Their pain and disability can persist despite the best available medical treatments, and only a small percentage of cases result from an identified pathological condition or anatomical defect that may be correctable with spine surgery. Their ability to work or be productive is seriously affected by the condition and the resulting days lost from work, disability benefits and health resource utilization put a significant burden on individuals, families, communities, industry and governments.
Further information can be found at www.mainstay‑medical.com
CAUTION – in the United States, ReActiv8 is limited by federal law to investigational use only.
PR and IR Enquiries:
Consilium Strategic Communications (international strategic communications – business and trade media)
Chris Gardner, Mary-Jane Elliott, Jessica Hodgson, Hendrik Thys
Tel: +44 203 709 5700 / +44 7921 697 654
FTI Consulting (for Ireland)
Tel: +353 1 765 0886
NewCap (for France)
Tel: +33 1 44 71 98 53
AndreasBohne.Com/Kötting Consulting (for Germany)
Tel : +49 2102 1485368
Email : firstname.lastname@example.org
Tel: +49 69 75913293
LifeSci Advisors, LLC
Tel: +1 (212) 915-2578
Fergal Meegan or Barry Murphy
Tel: +353 1 679 6363
Email: email@example.com or firstname.lastname@example.org